Mefloquine is recommended in international health guidelines for preventing malaria in travellers.
Results
We identified 527 articles that required full-text retrieval; of these 17 were unique publications that reported deaths or parasuicide. Eight unique publications had sufficient detail to be included in causality assessment. We identified 2 deaths with a probable association that appeared to be idiosyncratic drug reactions; we categorised the remaining 8 deaths as "unlikely" to be related to mefloquine, or "unclassifiable". There was one parasuicide with a possible causal association.
There were 9 additional publications that searched spontaneous drug reporting databases; none provided sufficient detail to perform a causality assessment.
Introduction
Mefloquine has been widely available for use in Europe and the USA since the late 1980s. Many international health guidelines recommend mefloquine as standard prophylaxis in travellers to malaria endemic areas [1, 2, 3, 4] .
Mefloquine often causes mild headaches and dizziness [5] , but also vivid dreams and mood changes.
These effects have given rise to beliefs that the drug can result in suicide and psychosis. The occurrence, frequency and severity of these events and their attribution to mefloquine have been the subject of heated debate. In 2013, the US Food and Drug Administration (FDA) issued a "boxed warning" about mefloquine and risk of neurological or psychiatric events, with special warnings to be given to users. However, there remains a lack of clarity over the evidence base for this, and concerns these developments limit the use of an important drug in preventing malaria in travellers [6] .
Nevertheless, recently the UK Defence Committee concluded that mefloquine should only be used as a "drug of last resort" [7] .
The side-effects of mefloquine are well documented: abnormal dreams, insomnia, anxiety and depressed mood, as well as nausea and dizziness. The recent Cochrane Review documents this and estimates absolute effects [8] . Whilst this is not contested, what is uncertain is the evidence related to the drug causing death or suicide.
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In parallel with the preparation of the new edition of the Cochrane Review, we have conducted a systematic review of all reports of deaths, which we report here. This review draws on all possible reports, and applies a standard causality framework as this appears to be the most useful approach to critically appraise and assess the quality of these reports. In light of suggestions that mood change and suicide with the drug were connected, we also sought and appraised reports of parasuicide. The author team wrote and agreed the review protocol in advance [10] , and the objectives were as follows.
• To identify all possible reported deaths or episodes of parasuicide associated with mefloquine used at a prophylactic dose in publicly available literature.
• To critically appraise each case using a formal causality assessment.
2 Materials and methods 2.1 Inclusion criteria
Types of studies
We included all forms of prospective and retrospective studies of individual case reports or reviews of case reports that reported deaths or parasuicide. Newspaper articles were excluded. • Parasuicide (the act of committing suicide without the resulting death. Objectively and subjectively, the actions taken were intended to result in death).
Search strategy
We attempted to identify all relevant studies regardless of language or publication status (published, unpublished, in press and ongoing).
We searched the following databases using the search terms described in Figure 1 We checked the reference lists of each included paper for other potentially relevant studies. At fulltext screening stage, we compiled a database of any articles that mentioned death or parasuicide associated with mefloquine prophylaxis. We then checked the reference list of each of these papers and retrieved the original full-text case reports (where available).
For each published review of deaths due to mefloquine, including the withdrawn Cochrane Review [9] , we compared the primary citation for each death and compiled a list of the unique death reports. We contacted authors, where necessary, to obtain full descriptions of any deaths or episodes of parasuicide. 
Methods

Selection of studies
Data extraction and management
Two authors independently extracted data using a standardized and pre-piloted data collection form.
When available, we extracted the following information.
• Study: design, year, country of origin and country of malaria exposure.
• Intervention: drug dose during prophylaxis, use of a loading dose, number of doses taken, frequency of drug administration and use of any co-interventions.
• Participant: age, sex, body mass index (BMI), occupation, past medical history, proceeding symptoms, use of other medications (prescribed and recreational).
• Outcome: circumstances of death or parasuicide, timing in relation to treatment, duration and frequency of monitoring, method of detection.
Assessment of causality
We extracted data on all reports of death. Two authors independently critically appraised each report using 'The WHO-UMC system for standardised case causality assessment' tool' (Figure 2 ) [11] . This classifies the event into "certain", "probable", "possible" or "unlikely" depending on the strength of the association with the study drug. Where the information presented was poor or conclusions could not be drawn, we categorised the event as "unclassifiable". We have included all reports in the final review, regardless of classification. Any disagreement was resolved through discussion, and where necessary a third author was consulted.
Dealing with missing data
If data from the papers was insufficient, unclear or missing, we contacted the authors for additional information. Re-challenge information is not required to fulfil this definition.
This definition has less stringent wording than for "certain" and does not necessitate prior knowledge of drug characteristics or clinical adverse reaction phenomena. As stated, no re-challenge information is needed, but confounding drug administration and underlying disease must be absent. This definition is used when insufficient information is available to perform a causality assessment. Figure 2 . Framework for causality assessment [11] . These descriptions are based on the WHO-UMC causality assessments, with appropriate modifications for this review.
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Description of studies
Our electronic search was performed on 11 July 2017 and identified 2523 citations. Screening the reference list of all papers referring to deaths associated with mefloquine prophylaxis identified an additional 2 case reports. After removal of duplicates, 2521 articles were retrieved.
Of these, we excluded 1993 at the title and abstract screening stages and retrieved 528 full-text reports. We did not identify any ongoing studies or studies awaiting classification.
Of these 528, 457 did not meet our inclusion criteria and were excluded for the reasons detailed in Figure 3 .
A total of 71 studies mentioned mefloquine being potentially linked to death or parasuicide. Of these, 17 were unique publications which referred to death or parasuicide in users of mefloquine prophylaxis. Fifty-four articles were excluded after full-text assessment.
Eight publications were individual reports of death or parasuicide and are included with a full causality assessment (Table 1) . Three of these were case reports in peer-reviewed journals and one additional case report was from a drug safety newsletter. Two were retrospective cohort studies and one was a randomised controlled trial in pregnant women. The eighth publication was a review article about suicide in US soldiers.
Nine publications included multiple reports of death reported in reviews that had been derived from spontaneous drug reporting databases. All of these reports had insufficient information to apply causality assessment ( 
The 54 publications excluded after full-text assessment are detailed in Table 3 . Thirty articles referred to publications included in our main analysis; 7 made reference to mefloquine being linked to suicide, but did not provide a reference; 6 referred to case reports of mefloquine being linked to suicide, however, the reference(s) provided did not include any reports of death or parasuicide; 3
were case reports in which mefloquine was used at treatment dose; 3 did not provide sufficient detail to meet our inclusion criteria (for example, dose not specified); 3 referred to a death in a user of mefloquine prophylaxis but the reference provided was a newspaper article; and 2 were excluded for other reasons. 
Causality assessment
For the 8 publications that we applied the formal causality assessment, the results are shown in Table 1 . We identified 2 deaths with a probable causal association with mefloquine prophylaxis, and 1 parasuicide with a possible causal association. The probable deaths were caused by what appeared to be idiosyncratic drug reactions (pulmonary fibrosis; exfoliative illness with neutropenia). We classified 8 other individual reports of death as "unclassifiable" or "unlikely" using the causality framework.
Discussion
We identified two deaths with a probable causal association with mefloquine prophylaxis, and one parasuicide with a possible causal association. The application of rigorous procedures, ensuring deaths were not double counted, and applying a causality assessment results in a much smaller number of deaths than previously cited in the discussion section of an older edition of the Cochrane Review on the topic which reported that 22 deaths, including 5 suicides, were caused by mefloquine [8, 30] .
Whether the reported deaths were correctly attributed to the use of mefloquine prophylaxis is an important clinical question, as the risk of death in a previously healthy population is unacceptable to both prescribers and users of malaria prophylaxis. As this old data set was contained as an annex with no methods, we have repeated the analysis with a new search strategy and formal causality assessment. Our assessment indicates the previous estimate was incorrect.
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Whilst we would agree these are difficult decisions, our approach has been to maintain the judgements made by the team, rather than adjusting in the light of subsequent comments on selected cases. Determination of causality is very complicated where people are in highly stressful situations which in themselves can cause sleeplessness and stress; and psychological and psychiatric disturbances after active military duty can be common: Marvasti 2013 in Table 1 illustrates this [16] .
Designing a systematic review to assess the risk of a rare outcome of an intervention, such as death, poses specific methodological challenges. Randomised controlled trials and cohort studies are usually not powered to detect uncommon outcomes. Therefore, systematic evaluation of these outcomes requires the inclusion of other study designs such as case reports, case series and spontaneous reporting systems [31] . These study designs have their own limitations [32] .
One problem with these methods of pharmacovigilance is that death is too rare an outcome to allow a robust statistical analysis to evaluate the likelihood that a particular treatment is the cause of a particular adverse event [33] . Therefore, each individual case report requires a formal causality assessment. Many different methods have been proposed; however, so far no approach has shown consistent and reproducible results and therefore there is currently no gold standard methodology [33] . The WHO-UMC system used in this paper was designed as a combined assessment, considering the clinical-pharmacological aspects of the case history and the quality of the recorded observations [11] . Despite its limitations, this remains the most widely used method in causality assessment, largely due to its ease of use and easy-to-follow classification system [33] .
However, regardless of the methodology used to determine causality, our main limiting factor was the poor reporting of this topic within the academic literature. Despite extensive searching, we only found a few reports that provided us with sufficient detail to perform a formal causality assessment.
Even where case reports did provide sufficient information, quality concerns remained; a good M A N U S C R I P T
15 example comes from a widely-reported case [34, 35] that contained significant discrepancies regarding the dose of mefloquine across different publications of the same report. We received confirmation through personal communication with the author that mefloquine was in fact taken at a treatment dose for presumed malaria illness and thus excluded from our analysis (Jousset, personal communication).
Case reports or case series are absolutely confounded by publication bias. In other words, if the event occurs then such cases are likely to be written up and reported in a journal, whereas if there is no event they will not be reported. However, what was striking here was how few reports we found, despite exhaustive searching.
Publications that included analyses of spontaneous drug reporting databases provided additional interesting information. These databases were developed after the thalidomide incident and are used in the identification of signals of new, rare and serious adverse drug reactions [36] . They provide a large volume of reports, but often contain little or no additional information, and usually have insufficient detail to critically appraise causality. These reports have appeared in previous reviews of severe adverse effects of mefloquine, but when we examined the information reported none had sufficient detail to apply the causality framework. We have intentionally not provided a summary estimate of the number of deaths associated with mefloquine use in these analyses ( Table   2 ). Collections of adverse reactions to spontaneous reporting systems occur from all available sources including the lay and scientific press, national and international regulatory authority databases, consumers and medical and paramedical practitioners. Therefore, it is likely that events are reported more than once, by different doctors or by both doctor and patient, as well as to more than one spontaneous reporting system. There are also discrepancies between different searches of the same database. Only one of these analyses performed a causality assessment of the reported cases [21] , and there was insufficient detail for us to provide a robust estimate ourselves.
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Our findings differ from previous analyses of the same topic [9, 30] , which have included several references to grey literature, including newspaper articles; in our opinion this should be avoided in the scientific analysis of controversial topics such as this one.
Overall, the number of deaths that we could reliably attribute to the prophylactic use of mefloquine was much lower than has previously been reported. However, due to poor reporting of this topic within the literature, we cannot provide a single summary estimate.
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. Case reports of deaths in users of mefloquine prophylaxis: causality assessment
Primary reference
Type of study
Clinical summary Classification Justification
Anon 2001 [12, 13] Case report in a peerreviewed journal A previously healthy 22 year old began mefloquine prophylaxis 1 week prior to travel. 8 days later he developed fever, chills, headache and cough. He was diagnosed with malaria and bronchopneumonia and was treated orally with halofantrine, dirithromycin and acetylcysteine. Two days later, he stepped from a car, complained of a 'head rush', then collapsed and died. Autopsy revealed a previously undiagnosed atypical asymmetric hypertrophic cardiomyopathy.
Unlikely
Halofantrine has been commonly associated with cardiac arrhythmias as it causes prolongation of the QT interval (it was discontinued for this reason) and is the more likely cause of a potential dysrhythmia in this patient with previously undiagnosed cardiomyopathy.
Eick-Cost 2017 [14] Retrospective cohort study
Two soldiers who received a prescription for mefloquine (from a cohort of 36,538) committed suicide. In the same cohort study, 15 soldiers who received a prescription for doxycycline (cohort size 318,421), and one who received a prescription for atovaquone-proguanil also committed suicide (cohort size 12,881).
Unclassifiable This was a retrospective analysis of prescription data and the individuals were never contacted. Therefore, it is not possible to confirm whether the mefloquine prescriptions was ever taken and, if so, the occurrence of this event in relation to treatment use. There is also no past medical history and no information about any co-medications for either participant. the trip, she experienced rash and fever at night, but was afebrile during the day. She was given an antibiotic for a suspected infection, although subsequent tests revealed no evidence of this. On her return, she was hospitalized with suspected inflammatory disease, but no specific diagnosis was given. She was continued on the mefloquine and received corticosteroids which led to some improvement. After 45 days, her general state of health worsened. She started to cough and developed interstitial pneumonitis. Mefloquine was discontinued. A chest radiograph showed bilateral infiltration confluent in the lung. She was intubated and ventilated due to her rapidly progressive lung failure. A pulmonary biopsy showed autoimmune interstitial alveolitis. She was treated with high dose corticosteroids, plasmapheresis and immunoglobulins. After five weeks of extracorporeal membrane oxygenation (ECMO) treatment, the patient died suddenly.
no alternative drug regime used to provide an alternative explanation. Symptoms continued to progress despite the withdrawal of mefloquine, making de-challenge difficult to analyse. This is presented as a series of 12 cases where mefloquine was associated with pneumonitis. Retrospective cohort study Two individuals who received a prescription for mefloquine (from a cohort of 16,491) committed suicide during the 'follow up period' of this retrospective cohort study. Both were males and had stopped treatment over 90 days before the date of the event.
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Unclassifiable This was a retrospective analysis of prescription data and the individuals were never contacted. Therefore, it is not possible to confirm whether the prescriptions were ever taken and if so, the duration of treatment. There is also no past medical history and no information about any comedications for either participant.
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Nosten 1994 [19] Randomised controlled trial "One woman in the mefloquine group died of septic shock after an emergency caesarean section for obstructed labour"
Unlikely This patient died of complications related to labour rather than mefloquine use.
Rodor 1990 [20] Case report in a peerreviewed journal
Case of 22-year-old woman who took a 250 mg of mefloquine for malaria prophylaxis. On day 2 after intake, she experienced episodes of crying, emotional detachment, and low mood. Her symptoms ameliorated on day 5 and 6. One week later (following the next dose) there was a relapse of symptoms with ideas of reference, of guilt, of death, and feelings of body transformation. Five days later she was hospitalized after a suicide attempt by drowning. Physical examination and routine blood tests, ECG and EEG were normal. She was discharged from hospital three weeks later.
Possible
The symptoms occurred in a reasonable time sequence to starting mefloquine prophylaxis. The patient was released from hospital after 3 weeks, which is the half-life of mefloquine. No information is provided regarding this patient's past medical history or any other medications she had taken or was currently taking. Reports 8 cases of suicide in participants who had used mefloquine, all male aged 23-55 years old. Three cases had preexisting psychiatric disorders, 4 did not and one case was unknown. In four cases the latency period was 3-47 days. In 2 cases the suicide occurred months or years after prophylaxis use. WHO 1991 [25] 
